Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hanan Alharthy has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Second-line CD19 CAR T vs platinum salvage and autologous stem cell transplant for primary mediastinal B-cell lymphoma

    by Xi Yang, Henry Dumke, Swetha Thiruvengadam, Christine Argao, Joseph G. Schroers-Martin, Sree Lanka, Yazeed Sawalha, Hanan A. Alharthy, Sairah Ahmed, Izel Okcu, et al.

    Primary mediastinal B-cell lymphoma (PMBCL) is a rare form of large B-cell lymphoma (LBCL), with ∼90% of patients cured with frontline treatment. For relapsed or refractory (R/R) disease, the optimal treatment is unclear. CD19 chimeric antigen receptor T-cell (CAR T) therapy has been established as the preferred second-line (2L) treatment for primary refractory or early-relapsing LBCL based on the overall survival benefits observed in landmark phase 3 trials. However, patients with PMBCL were underrepresented in these pivotal studies. This study evaluated outcomes of 252 patients treated with 2L therapies for R/R PMBCL at 14 US institutions between 2001 and 2025. Platinum-based salvage therapy with intent to proceed to high-dose therapy and autologous stem cell transplant (HDT/ASCT; platinum cohort) and CD19 CAR T therapy (CAR T cohort) were given as 2L therapies in the real-world setting in 157 and 26 patients, respectively. Overall response rate (ORR), complete response (CR) rate, and median progression-free survival (PFS) were significantly higher in the CAR T cohort compared with the platinum cohort (ORR, 91.3% vs 44.2%; P< .001; CR, 65.2% vs 14.7%; P< .001; median PFS, not reached vs 3.5 months; hazard ratio, 0.28; 95% confidence interval, 0.15-0.54; P = .001). No significant difference was observed in overall survival. This study demonstrated the superior response rate and PFS of CD19 CAR T therapy over platinum-based salvage therapy with intent to proceed to HDT/ASCT as 2L treatment for R/R PMBCL.

  • Open Access

    Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study

    by Elizabeth M. Corley, Moaath K. Mustafa Ali, Hanan Alharthy, Kathryn A. F. Kline, Danielle Sewell, Jennie Y. Law, Seung Tae Lee, Sandrine Niyongere, Vu H. Duong, Maria R. Baer, et al.

    The prognostic significance of the length of internal tandem duplication (ITD) insertions in mutant FLT3 genes in acute myeloid leukemia (AML) is controversial. We conducted a retrospective study to evaluate the correlation between the ITD base-pair (bp) insertion length and clinical outcomes. The mutational status of the FLT3 gene was evaluated in 402 of 467 consecutive AML patients treated at the University of Maryland Greenebaum Comprehensive Cancer Center between 2013 and 2020; 77 had FLT3-ITD mutations. Patients were divided into three cohorts based on bp insertion length (53 (>66th percentile)). The median overall survival (OS) of patients was 16.5 months (confidence interval (CI) 7.3-NA), 18.5 months (CI 7.3-NA), and 21.9 months (CI 19.1-NA) (p = 0.03) for the 53 bp insertion length cohorts, respectively. The adjusted median event-free survival (EFS) for the ITD insertion lengths >30, 30–53, and >53 bp was 11.1 months (CI 2.8–16.5), 5.2 months (CI 2.9–12.6), and 9.1 months (CI 5.4-NA) (p = 0.5), respectively. Complete remission (CR) rates were 64% (53 inserted bp) (p = 0.23). For patients treated with gilteritinib and midostaurin, the unadjusted median OS was not statistically significantly different between cohorts.


  • Open Access

    Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

    by Victor Manuel Orellana-Noia, Daniel R. Reed, Ashley Alesia McCook, Jeremy Michael Sen, Christian M. Barlow, Mary-Kate Malecek, Marcus Watkins, Brad S. Kahl, Michael A. Spinner, Ranjana Advani, et al.

    Prophylaxis is commonly used to prevent central nervous sy stem (CNS) relapse in diffuse large B-cell lymphoma (DLBCL), with no clear standard of care. We retrospectively evaluated 1162 adult patients across 21 US academic centers with DLBCL or similar histologies who received single-route CNS prophylaxis as part of frontline therapy between 2013 and 2019. Prophylaxis was administered intrathecally(IT) in 894 (77%) and using systemic high-dose methotrexate (HD-MTX) in 236 (20%); 32 patients (3%) switched route due to toxicity and were assessed separately. By CNS-International Prognostic Index (IPI), 18% were considered low-risk, 51% moderate, and 30% high. Double-hit lymphoma (DHL) was confirmed in 243 of 866 evaluable patients (21%). Sixty-four patients (5.7%) had CNS relapse after median 7.1 months from diagnosis, including 15 of 64 (23%) within the first 6 months. There was no significant difference in CNS relapse between IT and HD-MTX recipients (5.4% vs 6.8%, P = .4), including after propensity score matching to account for differences between respective recipient groups. Weighting by CNS-IPI, expected vs observed CNS relapse rates were nearly identical (5.8% vs 5.7%). Testicular involvement was associated with high risk of CNS relapse (11.3%) despite most having lower CNS-IPI scores. DHL did not significantly predict for CNS relapse after single-route prophylaxis, including with adjustment for treatment regimen and other factors. This large study of CNS prophylaxis recipients with DLBCL found no significant difference in CNS relapse rates between routes of administration. Relapse rates among high-risk subgroups remain elevated, and reconsideration of prophylaxis strategies in DLBCL is of critical need.